These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25257311)

  • 1. The RAS and YAP1 dance, who is leading?
    Corbo V; Ponz-Sarvise M; Tuveson DA
    EMBO J; 2014 Nov; 33(21):2437-8. PubMed ID: 25257311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover.
    Hong X; Nguyen HT; Chen Q; Zhang R; Hagman Z; Voorhoeve PM; Cohen SM
    EMBO J; 2014 Nov; 33(21):2447-57. PubMed ID: 25180228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP1--friend and foe.
    Yee KS; O'Neill E
    Cell Cycle; 2010 Apr; 9(8):1447-8. PubMed ID: 20372091
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical protein kinase C induces cell transformation by disrupting Hippo/Yap signaling.
    Archibald A; Al-Masri M; Liew-Spilger A; McCaffrey L
    Mol Biol Cell; 2015 Oct; 26(20):3578-95. PubMed ID: 26269582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. αE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway.
    Li P; Silvis MR; Honaker Y; Lien WH; Arron ST; Vasioukhin V
    Genes Dev; 2016 Apr; 30(7):798-811. PubMed ID: 27013234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis.
    Guo C; Wang X; Liang L
    Int J Clin Exp Pathol; 2015; 8(2):1690-7. PubMed ID: 25973055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP activates the Hippo pathway in a negative feedback loop.
    Dai X; Liu H; Shen S; Guo X; Yan H; Ji X; Li L; Huang J; Feng XH; Zhao B
    Cell Res; 2015 Oct; 25(10):1175-8. PubMed ID: 26315483
    [No Abstract]   [Full Text] [Related]  

  • 8. MST1/2 and YAP1 gene expression in acute myeloid leukemia.
    Safari S; Movafagh A; Zare-Adollahi D; Ghadiani M; Riazi-Isfahani S; Safavi-Naini N; Omrani MD
    Leuk Lymphoma; 2014 Sep; 55(9):2189-91. PubMed ID: 24303784
    [No Abstract]   [Full Text] [Related]  

  • 9. YAP1 meets tumor suppression.
    Strano S; Blandino G
    Mol Cell; 2007 Sep; 27(6):863-4. PubMed ID: 17889659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YAP1 takes over when oncogenic K-Ras slumbers.
    Greten FR
    Cell; 2014 Jul; 158(1):11-2. PubMed ID: 24995973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.
    Kang W; Huang T; Zhou Y; Zhang J; Lung RWM; Tong JHM; Chan AWH; Zhang B; Wong CC; Wu F; Dong Y; Wang S; Yang W; Pan Y; Chak WP; Cheung AHK; Pang JCS; Yu J; Cheng ASL; To KF
    Cell Death Dis; 2018 Jan; 9(2):92. PubMed ID: 29367737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome.
    Rybarczyk A; Klacz J; Wronska A; Matuszewski M; Kmiec Z; Wierzbicki PM
    Oncol Rep; 2017 Jul; 38(1):427-439. PubMed ID: 28504812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
    Sun D; Li X; He Y; Li W; Wang Y; Wang H; Jiang S; Xin Y
    Oncotarget; 2016 Dec; 7(49):81062-81076. PubMed ID: 27835600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
    Ye S; Lawlor MA; Rivera-Reyes A; Egolf S; Chor S; Pak K; Ciotti GE; Lee AC; Marino GE; Shah J; Niedzwicki D; Weber K; Park PMC; Alam MZ; Grazioli A; Haldar M; Xu M; Perry JA; Qi J; Eisinger-Mathason TSK
    Cancer Res; 2018 May; 78(10):2705-2720. PubMed ID: 29490948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer: Targetable YAP1-AR interaction key to disease progression.
    Thoma C
    Nat Rev Urol; 2015 Nov; 12(11):596. PubMed ID: 26390969
    [No Abstract]   [Full Text] [Related]  

  • 16. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
    Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
    Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
    Nagashima S; Bao Y; Hata Y
    Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation.
    Villalonga P; Fernández de Mattos S; Ridley AJ
    J Biol Chem; 2009 Dec; 284(51):35287-96. PubMed ID: 19850923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation.
    Peng C; Zhu Y; Zhang W; Liao Q; Chen Y; Zhao X; Guo Q; Shen P; Zhen B; Qian X; Yang D; Zhang JS; Xiao D; Qin W; Pei H
    Mol Cell; 2017 Nov; 68(3):591-604.e5. PubMed ID: 29100056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
    Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
    Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.